Viking Therapeutics: Phase-3 Study Completed on Schedule – Analyst Targets Signal Potential

Viking Therapeutics (NASDAQ: VKTX) has achieved an important milestone in clinical development: The California-based biotech company specializing in metabolic and endocrine disorders has completed patient recruitment for the Phase-3 VANQUISH-2 study on schedule. The stock traded at $33.70 on April 7, 2026, representing a level approximately 78% above the 52-week low of $18.92.

Broad Pipeline with Four Parallel Late-Stage Studies

Viking Therapeutics is pursuing an ambitious clinical strategy: By the end of 2026, the company plans to conduct four late-stage studies simultaneously. This parallel approach enables the company to advance multiple indications concurrently and distribute development risk across different programs. The successful completion of patient recruitment for VANQUISH-2 underscores management's operational execution capability.